A Phase I/II Study of Combination of Azacitidine, Venetoclax and Pevonedistat in Patients with Newly-Diagnosed Secondary Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) with Hypomethylating Agent (HMA) Failure

Autor: Ong, Faustine *, Garcia-Manero, Guillermo, Montalban-Bravo, Guillermo, Alvarado, Yesid, Ohanian, Maro *, Konopleva, Marina, Jabbour, Elias, Jain, Nitin, Borthakur, Gautam, DiNardo, Courtney D., Daver, Naval, Issa, Ghayas C., Sasaki, Koji, Chien, Kelly S., Takahashi, Koichi, Andreeff, Michael, Muftuoglu, Muharrem, Delumpa, Ricardo *, Mayor, Ejiroghene *, Loiselle, Christopher *, Waller, Lourdes *, Banks, Glenda *, Kantarjian, Hagop, Cortes, Jorge E., Short, Nicholas
Zdroj: In Blood 15 November 2022 140 Supplement 1:6206-6208
Databáze: ScienceDirect